麻豆传媒

Director of the Blood and Marrow Transplant Center, Roswell Park Cancer Institute Areas of expertise: Bone marrow transplant, leukemia, lymphoma, multiple myeloma, blood cancer, hematologic oncology

Physician-scientist Dr. David Maloney is at the forefront of clinical trials to develop cell therapies for blood and other cancers, including understanding side effects of CAR T’s and how to deliver them in outpatient settings. A renowned researcher and clinician focusing on cancer immunotherapies and CAR T-cell therapies, he recently presented findings from the TRANSCEND trial for CD19 CAR T. This study showed that patients had improved quality-of-life (reduced fatigue and pain symptoms) starting six months after receiving CAR T-cell therapy. Dr. Maloney focuses on using genetically engineered T cells (such as CAR-T) to treat patients with leukemia, lymphoma, myeloma and selected other cancers without causing graft vs. host disease that has been associated with transplantation. He was instrumental in developing and testing rituximab, the first antibody-based cancer drug on the market – one that has transformed the treatment of certain leukemias and lymphomas. He is also an expert on blood-forming (hematopoietic) stem cell transplantation (HCT) in using a matched donor’s (allogeneic) or a patient’s own (autologous) stem cells in treatments for patients with hematologic malignancies. Recognizing that standard pre-transplant regimens are too toxic for many patients, Dr. Maloney and Fred Hutch colleagues are evaluating approaches that use antibodies to deliver radioactivity or cancer-killing drugs directly to tumors. They have also developed a less toxic, “reduced intensity” (nonmyeloablative) regimen that can more safely provide long-term remissions for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin Lymphoma (NHL) and myeloma after allogeneic HCT. Autologous HCT followed by reduced intensity allogenic HCT (tandem HCT) has proven effective for refractory NHL and myeloma patients. Dr. Maloney and colleagues have learned that nearly all of the anti-tumor activity of allogeneic HCT comes from the specific graft-vs-tumor activities of donor immune T cells, showing that antitumor immunity can be curative. Unfortunately, these T cells can also cause dangerous “graft-vs-host” effects on normal tissues. Dr. Maloney continues exploring the use of antibodies as anti-cancer therapies, including newer anti-CD20 antibodies (e.g. ofatumumab, Arzerra®) for NHL patients, as well as radiolabeled antibodies, drug-carrying antibodies and unlabeled antibodies as targeted pre-transplant “conditioning” or as “maintenance” to extend remissions after allogeneic transplantation. As medical director of the Cellular Immunotherapy Integrated Research Center at Fred Hutch, Dr. Maloney cares for patients at the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance, the Hutch’s clinical-care partner. He is also professor of medicine in the Division of Oncology at the University of Washington.

Namrata Chandhok, M.D. is an Assistant Professor of Clinical Medicine (Hematology) at the University of Miami Miller School of Medicine/ Sylvester Comprehensive Cancer Center. She received her MD from the George Washington University School of Medicine in Washington, D.C, completed her residency in Internal Medicine at Tufts Medical Center in Boston, MA and fellowship in Hematology/ Oncology at Yale University School of Medicine/ Yale New Haven Hospital in New Haven, CT. Dr. Chandhok specializes in the management of myeloid disorders, which include myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML). Her research focuses on the use of novel therapies to treat cancer and identification of cancer dependencies and vulnerabilities in the early stages of cancer that can be used to develop cancer prevention strategies. She is also deeply invested in advancing health equity in cancer care.

Dr Sekeres has focused on leukemias, and particularly myelodysplastic syndromes and acute myeloid leukemia in older adults, for two decades. He has developed innovative therapies for these cancers; helped define the genetics of leukemia and related blood and bone marrow cancers along with clinical correlates; helped redefine prognostication, including innovative methods using machine learning and artificial intelligence; and helped define the epidemiology and patient reported outcomes in these conditions. He has also chaired the FDA’s Oncologic Drugs Advisory Committee and is an expert on cancer regulatory issues, and is a widely published essayist focused on patient-doctor communication, with 60 essays in The New York Times.

Bone Marrow Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndrome Specializing In: Cellular Therapies, including stem cell transplantation, CAR-T cell therapies, TILs, TCR gene therapies Biography: My research is dedicated to developing gene-engineered cell therapies that target cancer cells in pre-clinical models. The goal of this research is to identify optimal cell therapies that can then be evaluated in cancer patients. It is my goal that our innovative laboratory and clinical research will lead to therapeutic options for patients with cancers. Positions Roswell Park Comprehensive Cancer Center Vice Chair for Cellular Therapies Senior Vice President and Associate Director for Translational Research Department of Medicine Background Education and Training: 1997-2004 - PhD - Duke University School of Medicine, Durham, NC 1995-2004 - MD - Duke University School of Medicine, Durham, NC 1991-1995 - BS - Biochemistry/Chemistry, Texas Christian University, Forth Worth, TX Residency: 2004-2006 - Resident, Department of Medicine, New York Presbyterian Weill/Cornell, Cornell Medical Center, New York City, NY Fellowship: 2010-2011 - Research Fellow, Department of Medicine, Division of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY 2006-2010 - Clinical Fellow, Department of Medicine, Division of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY Professional Memberships: Society of Immunotherapy for Cancer American Society of Hematology American Society of Clinical Oncology American Association for Cancer Research American Association of Immunologists Professional Experience: 2021-2022 - Senior Member, Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 2016 –2022 - Medical Director, Cell Therapy Facility, H. Lee Moffitt Cancer Center, Tampa, FL 2015-2022 - Associate Professor, Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL 2015-2021 - Associate Member, Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL 2014–2015 - Assistant Professor, Department of Medicine, Division of Hematology and Oncology, School of Medicine, Vanderbilt University, Nashville, TN 2014-2015 - Assistant Professor, Department of Cancer Biology, School of Medicine, Vanderbilt University, Nashville, TN 2014-2015 - Assistant Member, Vanderbilt-Ingram Cancer Center, Nashville, TN 2011–2013 - Clinical Instructor, Department of Medicine, New York-Presbyterian Weill Cornell Medical Center, New York, NY 2011– 2013 - Assistant Attending Physician, Leukemia Service, Department of Medicine, Division of Hematologic Oncology, Memorial Hospital, New York, NY 2011–2013 - Assistant Member, Memorial Sloan Kettering Cancer Center, New York, NY Honors & Awards: 2018 - Miles for Moffitt Award 2018 - National Trio Achievement Award 2015 - Damon Runyon Clinical Investigator Award 2015 - SWASAP TRiO Achiever 2015 - TASSSP TRiO Achiever 2014 - ASCI Council Young Physician-Scientist Award 2012 - Amos Medical Faculty Development Program Scholar, American Society of Hematology 2011 - TRiO Achiever Award, Texas Christian University 2010 - K08 Mentored Clinical Scientist Career Development Award 2010 - Young-Investigator Award, American Society of Clinical Oncology 2010 - Clinical and Translational Science Center KL2 Scholars Award 2009 - Mortimer J. Lacher Fellow 2003 - Bernard Amos Immunology Graduate Student Research Award, Duke University 2001 - Sammuel DuBois Cook Graduate Student Award, Duke University 1995 - Summa Cum Laude, Texas Christian University 1995 - Phi Beta Kappa, Texas Christian University 1995 - Senior Scholar in Chemistry, Texas Christian University 1994 - Ronald E. McNair Fellowship for Undergraduate Research, Texas Christian University 1994 - Summer Honors Undergraduate Research Program, Harvard Medical School, Cambridge, MA 1993 - Honors Premedical Academy, Rice University, Houston, TX 1992 - M.D. Anderson Pre-Med Scholarship

Dr. Pongas is a board certified hematologist and oncologist with clinical experience in indolent and aggressive lymphomas. His research interest is the development of cancer therapeutics for B cell lymphomas and viral associated lymphomas. He has done significant laboratory work in Diffuse Large B cell lymphoma elucidating the therapeutic role of inhibiting various PI3K isoforms. He collaborates with clinical scientists to develop novel therapies in lymphomas and with laboratory scientists to study the mechanism of resistance to the therapies and ways to bypass it. With this approach he hopes to develop combinational therapies and increase the cure rates of various lymphomas.

Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX

Nitin Jain, M.D., is a Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee. He then completed clinical fellowship in Leukemia at MD Anderson followed by a Leukemia research fellowship at Memorial Sloan-Kettering Cancer Center. He then pursued fellowship in Hematology/Oncology at The University of Chicago. He joined as a faculty in the Department of Leukemia at MD Anderson in July 2012. Dr. Jain treats patients with acute and chronic leukemias with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). Dr. Jain's research interests focus on new drug development for patients with leukemia, especially CLL and ALL. Since 2021, he has also served as Director, Leukemia CAR-T Program within the Department of Leukemia, MD Anderson.
Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, checkpoint inhibitor in Richter transformation, JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, ponatinib in T-ALL, and off-the-self allogeneic CARTs in B-ALL. The trial combining ibrutinib and venetoclax was published in New England Journal of Medicine in 2019. He has published papers in prominent journals including NEJM, Lancet, JAMA Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, and others.

After completing my Internal Medicine training at Johns Hopkins in the Osler Medical Program (2005-2008), I subsequently completed Hematology/Oncology training at MD Anderson Cancer Center Fellowship Program (MDACC; 2008-2011). I was selected as a Chief Fellow in my second year of fellowship training. I obtained ABIM board certification in Internal Medicine, Hematology and Oncology, and continued my career at MDACC as an Assistant Professor in the Department of Leukemia (start date 07/2011). In September 2017, I was promoted to Associate Professor in the Department of Leukemia. I maintain an active clinical schedule, during which I see patients 2-full days per week; including 2-months of inpatient service per year. I have fellow teaching responsibilities as the Leukemia Hematology/Oncology Course Director and was the sole recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. I was recognized as our institution’s Faculty Educator of the Quarter in December 2022.
My clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Myeloproliferative Neoplasms (MPN) and Acute Myeloid Leukemia (AML). I have authored/co-authored over 265 publications in the medical literature (all available in PubMed). I have presented our group's work, as first author, in oral presentations at numerous national/international meetings: ASCO, ASH, EHA, AACR. Under the direct mentorship of Dr. Hagop Kantarjian, and Dr. Marina Konopleva, I have established our group's first, active, BPDCN clinic; which now serves as a worldwide referral base and has brought in many new patients to MDACC. This clinic continues to expand as one of the world’s most active BPDCN research programs with dedicated infrastructure and ample support for clinical and translational studies. For these efforts, I have been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020. I am the PI/co-PI of many active clinical trials in the Leukemia department, for a translational sample study of patients with BPDCN, and was awarded a grant for identifying prognostic biomarkers in patients with BPDCN. I have developed key collaborative projects and lead groups in the areas BPDCN, MPN and AML, with clinical, hematopathology and dermatopathology teams; both internally and externally. I serve as our department’s Executive Director for the MDACC Network, helping to improve and expand upon leukemia and malignant hematology collaborations and clinical trials networking, and am an active member of the ASH Communications Committee, currently serving a 4-year term.